![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Ranbaxy Laboratories Limited Gurgaon In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Cefuroxime axetil, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2002-176 - Rev 01
This Chemical Type CEP, issued on March 02, 2010, remains in force until April 28, 2017, ensuring its reliability within the pharmaceutical industry.
Substance Number 1300 associated with this CEP further emphasizes